A New Antibody For Treating Acute Lymphocytic Leukemia?
The new agent, a monoclonal antibody to CD22 with a toxin attached, is manufactured by Pfizer. It’s called inotuzumab ozogamicin.
writer, health care advocate, physician
The new agent, a monoclonal antibody to CD22 with a toxin attached, is manufactured by Pfizer. It’s called inotuzumab ozogamicin.
Prior to the program’s start, maternal mortality for women with sickle cell disease exceeded 9% at the teaching hospital. With team-based care, the death rate fell to 1%.
Blood specialists reported on practice-changing studies for sickle cell disease, including a large study of bone marrow transplant from matched sibling donors. A preliminary report looked at effects of GBT440, a novel oral agent that augments hemoglobin’s binding to oxygen.
The EPA suggests an action level for lead in water: it should be below 15 parts per billion. Because lead toxicity causes irreversible neurological damage, prevention is crucial.
The implications extend beyond cancer drugs. Biosimilars have the potential to significantly reduce the costs of modern health care for people with all kinds of illness
The kinase inhibitor offers a new option for people with polycythemia vera, a condition for which few drugs have been available.
These are reasonable questions. Ordinary people, patients and others, are seeking guidance on this – and not false, or patronizing reassurances – that Ebola is nothing to worry about.
U.S. doctors are scrambling to understand how the virus affects humans, and how best to treat those infected.
Yesterday evening Secretary of State Hillary Rodham Clinton was hospitalized for treatment and monitoring of a blood clot.